Columbus Regional Research Institute at Talbotton

Columbus, Georgia 31904

0 studies enrolling now · 2 studies all time

What they study most

COVID-19 Disease, Gastroesophageal Reflux Disease (GERD)

Studies at this site

• ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 — Completed
• Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) — Completed